Group 1 - Shandong Zhanggu received administrative regulatory measures from the Shandong Securities Regulatory Commission due to issues related to related party transactions, information disclosure violations, improper use of raised funds, and non-compliance in corporate governance [1] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, holding a 59.9% stake, which will focus on investing in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [2] - ST Mingjia's stock will be suspended for one day on December 19 due to the implementation of its restructuring plan [3] Group 2 - Baotai's application for the marketing authorization of BAT5906 has been accepted by the National Medical Products Administration [4] - Nanhua Futures has set the final price for its H-share public offering at 12 HKD per share, with trading expected to begin on December 22 [5] - Visionox plans to invest 3.918 billion yuan in the second phase of capital contribution to Hefei Guoxian, increasing its shareholding to 37.73% [6] Group 3 - Dafu Technology intends to transfer 49% of its stake in Dasheng Graphite at a base price of 206 million yuan [7] - Aorite has passed the GMP compliance inspection for its production lines [8] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a dividend of 0.09 yuan per share [9][10] Group 4 - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Jinhua Co. plans to apply for a comprehensive credit line of 185 million yuan from Guangfa Bank [12] - Huicheng Environmental Protection's private placement has been approved by the China Securities Regulatory Commission [13] Group 5 - Junwei Electronics has established a joint venture with Placo New Materials in Hong Kong [14] - Huaye Fragrance appointed Gao Ming as the deputy general manager [15] - Yongmaotai received a government subsidy of 17.2242 million yuan, accounting for 45.92% of its net profit for the last audited fiscal year [16] Group 6 - Haitian Flavoring plans a special dividend of 3 yuan per 10 shares, totaling 1.754 billion yuan [17] - Haizheng Pharmaceutical's subsidiary received a new veterinary drug registration certificate [18] - Hailianxun's share swap merger with Hangzhou Qilun has been approved by the CSRC [19] Group 7 - ST Shuangcheng's injection of bortezomib ANDA has been approved by the US FDA [20] - Tibet Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan [21] - Jiayuan Technology has set a preliminary transfer price of 39.93 yuan per share for its inquiry transfer [22] Group 8 - Jiemai Technology has invested in Beijing Critical Field Technology Co., Ltd. [23] - Zotye Auto plans to reach a settlement with SAIC Transmission Company regarding a contract dispute [24] - Xianju Pharmaceutical's application for the registration of estradiol tablets has been accepted [25] Group 9 - Xinya Electronics has established a subsidiary focused on urban rail transit technology [26] - Southern Precision has received a total credit line of 179 million yuan from ICBC and CCB [27] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [28] Group 10 - Whirlpool plans to sign a supplementary agreement regarding component procurement with Whirlpool Corporation [29] - Haixiang New Materials intends to sell part of its under-construction factory for 41.3774 million yuan [30] - Menohua's subsidiary's atorvastatin calcium raw material drug application has been approved [31] Group 11 - Beilu Pharmaceutical plans to use up to 500 million yuan of idle funds for cash management [32] - Jiangnan New Materials plans to invest 300 million yuan in a high-end copper-based core material project [33] - Jinqilin's CRH380D train brake pads have passed small-scale trials [34] Group 12 - China Chemical signed contracts worth 352.569 billion yuan from January to November 2025 [35] - Guanghuan New Network plans to apply for an additional credit line of 300 million yuan [36] - Zhengye Technology signed a 120 million yuan equipment procurement contract [38] Group 13 - Xinno's subcutaneous injection of secukinumab has achieved primary endpoint success in its Phase III clinical trial [39] - Qinglong Pipe Industry signed a procurement contract worth 55.2671 million yuan [40]

Core Viewpoint - Sichuan Road and Bridge (600039.SH) announced that China Post Life Insurance Co., Ltd. increased its stake in the company by purchasing 114,300 shares through the secondary market, raising its total holdings to 435 million shares, which represents 5% of the company's total equity [1] Summary by Relevant Sections - **Shareholding Increase** - China Post Life Insurance acquired 114,300 shares, accounting for 0.0013% of the total equity [1] - **Total Holdings** - After the increase, China Post Life Insurance holds 435 million shares, which is 5% of the total share capital of Sichuan Road and Bridge [1] - **Impact on Control** - The equity change does not trigger a mandatory bid and will not result in any changes to the company's controlling shareholder or actual controller [1]

四川路桥建设集团股份有限公司 关于股东权益变动的提示性公告 证券代码：600039 证券简称：四川路桥 公告编号：2025-136 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动为股东增持股份，不触及要约收购。 本次权益变动后，中邮人寿保险股份有限公司（以下简称中邮保险或信 息披露义务人）持有四川路桥建设集团股份有限公司（以下简称公司）股份 434,779,540股，占公司总股本的5.00%。 本次权益变动不会导致公司控股股东、实际控制人发生变化。 公司于2025年12月18日收到信息披露义务人中邮保险出具的《简式权益变 动报告书》。本次权益变动是中邮保险基于自身发展投资需求和支持上市公司 持续健康发展的规划安排进行长期投资，截至本公告披露日，中邮保险持有公 司股份为434,779,540股，占公司总股本的5.00%。现将本次权益变动具体情况公 告如下： 一、本次权益变动基本情况 证券代码：600039 证券简称：四川路桥 公告编号：2025-136 | | 动；依法须经批准的项目，经相关部门批准 ...

智通财经APP讯，四川路桥(600039.SH)发布公告，2025年12月17日，中邮人寿保险股份有限公司通过 二级市场买入股票的方式增持公司11.43万股，占公司总股本的0.0013%。增持后，中邮保险持有公司 4.35亿股，占公司总股本的5%。此次权益变动不触及要约收购，且不会导致公司控股股东、实际控制 人发生变化。 ...

签署日期：2025年12月18日 上市公司名称： 四川路桥建设集团股份有限公司 上市地点： 上海证券交易所 股票简称： 四川路桥 股票代码： 600039.SH 四川路桥建设集团股份有限公司 简式权益变动报告书 信息披露义务人： 中邮人寿保险股份有限公司 信息披露义务人声明 住址： 北京市西城区金融大街甲3 号B 座6 层、7 层、8 层 通讯地址： 北京市西城区金融大街甲3 号B 座6 层、7 层、8 层 股份变动性质： 股份增加 截至本报告书签署日，除报告书披露的信息外，信息披露义务人没有通过 任何其他方式增加或减少其在四川路桥中拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。信息披露义务人没 有委托或者授权其他任何人提供未在报告书中列载的信息和对本报告书做出任 何解释或者说明。 五、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗 漏，并对其真实性、准确性、完整性承担法律责任。 2 | ਮ | | --- | | | | 一、本信息披露义务人根据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司收购 管理办法》（ ...

四川路桥公告，中邮人寿保险股份有限公司于2025年12月17日通过二级市场买入股票方式增持公司 11.43万股，占公司总股本的0.0013%。权益变动后，中邮保险持有公司股份4.35亿股，占公司总股本的 5.00%。此次权益变动为股东增持股份，不触及要约收购，且不会导致公司控股股东、实际控制人发生 变化。 ...

四川路桥12月18日公告，中邮人寿保险股份有限公司于2025年12月17日通过二级市场买入股票方式增持 公司11.43万股，占公司总股本的0.0013%。权益变动后，中邮保险持有公司股份4.35亿股，占公司总股 本的5.00%。此次权益变动为股东增持股份，不触及要约收购，且不会导致公司控股股东、实际控制人 发生变化。 ...

Group 1 - The Sichuan Road and Bridge Investment Group Co., Ltd. announced the appointment of Zhang Sheng as the Party Secretary and Chairman of the company [3][5] - The company was established on May 28, 2021, through the merger of the former Sichuan Transportation Investment Group and Sichuan Railway Investment Group [4][6] - As of now, the group has total assets exceeding 1.5 trillion yuan, with over 500 wholly-owned and holding enterprises [4][6] Group 2 - The group includes five publicly listed companies: Sichuan Road and Bridge, Sichuan Chengyu, Shudao Equipment, Hongda Co., and New筑股份 [4][6] - The company operates in over 60 countries and regions, employing nearly 60,000 people [4][6] - Since its establishment, the group's major economic indicators account for about half of the total of provincial state-owned enterprises, ranking second among provincial transportation enterprises in terms of total assets [4][6]

Core Viewpoint - The Hongli Low Volatility ETF (512890) has shown strong performance and investor interest, with significant net inflows and a solid historical return since its inception in December 2018 [1][5][12]. Fund Performance - The Hongli Low Volatility ETF (512890) recorded a price of 1.176 CNY, reflecting a 0.43% increase, with a trading volume of 2.66 billion CNY, making it the top performer among similar ETFs [3][6]. - Since its establishment, the fund has achieved a return of 133.84%, significantly outperforming its benchmark and ranking 77th among 502 products [12]. Fund Inflows - The fund has attracted substantial capital, with net inflows of 7.9 billion CNY over the last 5 trading days, 4.7 billion CNY over the last 20 days, and 53 billion CNY over the last 60 days, indicating strong investor confidence [1][8]. Holdings Performance - The top ten holdings of the Hongli Low Volatility ETF exhibited mixed performance, with notable movements including a 2.03% increase in Nanjing Bank and a 1.46% decrease in COFCO Sugar [4][10]. Regulatory Environment - The China Securities Regulatory Commission (CSRC) is promoting long-term capital investment strategies and enhancing market stability, which supports the growth of equity public funds and index investment [11]. - The new "National Nine Articles" policy clarifies requirements for listed companies regarding market capitalization management and dividend distribution, further supporting the low volatility dividend strategy [11].

Core Viewpoint - The global yellow phosphorus (P4) supply is dominated by China, Vietnam, and Kazakhstan, with China contributing 82.6% of the total production capacity in 2024, amounting to 1.45 million tons [2][9]. Group 1: Yellow Phosphorus Production - Yellow phosphorus is primarily produced using electric furnace and blast furnace methods, with electric furnace being the dominant method in China due to its high yield and product purity [2][4]. - In 2024, global yellow phosphorus production capacity is projected to reach 1.755 million tons, with China accounting for 1.45 million tons [2][9]. - China's yellow phosphorus production has seen significant growth since the reform and opening up, reaching a production peak of 1.025 million tons in 2014 [2][9]. - Environmental policies have led to a decline in China's yellow phosphorus production since 2016, with production expected to fluctuate between 2020 and 2025 [2][9]. Group 2: Regional Production and Demand - The main production regions in China are Yunnan, Guizhou, Sichuan, and Hubei, with Yunnan being the largest producer, contributing 44.4% of the global total in 2024 [2][9]. - In 2024, China's yellow phosphorus production is expected to reach 857,100 tons, a 16.5% increase from the previous year [2][9]. - The domestic demand for yellow phosphorus is relatively stable, with a projected apparent demand of 741,000 tons in 2024, indicating a self-sufficient state [2][9]. Group 3: Application and Industry Structure - The primary applications of yellow phosphorus include phosphoric acid and glyphosate, which account for 35% and 31% of the total usage, respectively [2][9]. - The top five yellow phosphorus producers in China contribute to 29% of the national capacity, including companies like Guizhou Wengfu and Yunnan Xuanwei Phosphate [2][3]. - The yellow phosphorus industry is crucial for various sectors, including agriculture, industrial manufacturing, and new energy, impacting global supply chain stability [6][9].